Targeting Tumors with Special Liposomes
Author Information
Author(s): Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener R A
Primary Institution: University Hospital Zurich
Hypothesis
Can liposomes modified with anti-ED-B fibronectin antibodies effectively target and treat F9 teratocarcinoma tumors?
Conclusion
The study found that anti-ED-B scFv-liposomes significantly reduced tumor growth in mice compared to control liposomes.
Supporting Evidence
- Anti-ED-B scFv-liposomes showed a 62-90% reduction in tumor growth compared to control liposomes.
- ScFv-liposomes accumulated in tumors at higher concentrations than unmodified liposomes.
- Histological analysis revealed reduced tumor cell numbers after treatment with scFv-liposomes.
Takeaway
Researchers created special liposomes that can find and attack tumor cells, helping to shrink the tumors in mice.
Methodology
The study involved preparing liposomes with anti-ED-B scFv antibodies, testing their binding to tumor cells in vitro, and evaluating their therapeutic effects in vivo on mice with F9 teratocarcinoma tumors.
Potential Biases
Potential bias due to the small sample size and the specific tumor model used.
Limitations
The rapid clearance of scFv-liposomes from circulation may limit their effectiveness.
Participant Demographics
Female nude mice (CD-1)-nu/nu were used in the study.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website